Sparrow Pharmaceuticals Overview
- Founded
- 2013
- Status
- Private
- Employees
- 5
- Latest Deal Type
- Series A
- Latest Deal Amount
- $50.8M
- Investors
- 11
Sparrow Pharmaceuticals General Information
Description
Developer of novel, proprietary corticosteroid (CS) products intended for the care for Cushing's syndrome. The company's patented drugs (NCEs) are the basis for new proprietary drugs with steroid efficacy, inhibits a key enzyme of steroid metabolism which blocks a pathway that is responsible for many steroid side effects, thereby providing patients with access to drugs for autoimmune disease, blood cancer and transplanted organ.
Contact Information
Website
www.sparrowpharma.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
- 920 South West 6th Avenue
- Suite 1200
- Portland, OR 97204
- United States
+1 (312) 000-0000
Sparrow Pharmaceuticals Timeline
Sparrow Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 8. Later Stage VC (Series A) | 19-Jan-2021 | $50.8M | 000.00 | 000.00 | Completed | Clinical Trials - General |
| 7. Later Stage VC (Series A) | 13-Jan-2021 | 00.000 | 00.000 | Completed | Clinical Trials - General | |
| 6. Later Stage VC | 25-Jun-2020 | 00000 | 00.000 | Completed | Clinical Trials - General | |
| 5. Early Stage VC | 21-Aug-2019 | 00000 | 00000 | Completed | Startup | |
| 4. Grant | 15-Apr-2019 | 00000 | Completed | Clinical Trials - General | ||
| 3. Accelerator/Incubator | 01-Jan-2019 | Completed | Clinical Trials - General | |||
| 2. Accelerator/Incubator | 28-Oct-2014 | Completed | Startup | |||
| 1. Merger/Acquisition | Completed | Startup |
Sparrow Pharmaceuticals Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A | 0,000,000 | 00.000000 | 00 | 00.00 | 00.00 | 00 | 00.00 | 00.000 |
Sparrow Pharmaceuticals Executive Team (3)
Sparrow Pharmaceuticals Board Members (4)
| Name | Representing | Role | Since |
|---|---|---|---|
| Bruce Galton | Self | Board Member & Advisor | 000 0000 |
| Gayle Kirkpatrick | Sparrow Pharmaceuticals | Board Member & Advisor | 000 0000 |
| Klaus Veitinger Ph.D | Self | Board Member | 000 0000 |
| Peter Thompson | Self | Board Member | 000 0000 |
Sparrow Pharmaceuticals Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %ile
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialSparrow Pharmaceuticals Investors (11)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| OrbiMed | PE/Buyout | Minority | 000 0000 | 000000 0 | |
| RiverVest Venture Partners | Venture Capital | Minority | 000 0000 | 000000 0 | |
| US Venture Partners | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Keiretsu Forum Northwest | Angel Group | Minority | 000 0000 | 000000 0 | |
| Slojo Investments | Venture Capital | Minority | 000 0000 | 000000 0 |